drugset / Trial / NCT07231029

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

NCT07231029

Phase 1 Recruiting 24 enrolled Taisho Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment

Timeline

Start
2025-12-23
Primary completion
2026-10-26
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral

Indications

No indication recorded.